Robinson Healthcare is the owner of the UK’s market-leading, single-use surgical instrument brand - Instrapac. The acquisition continues Vernacare’s buy and build strategy and increases the Group’s turnover to £120m annually. Robinson Healthcare manufactures single-use instruments (injection moulded single-use sterile devices and steel-polymer composite devices), veterinary medicinal products, wet wipes (flow pack and sachet format), long term aural implantable ventilation tubes and cotton-based medical absorbents.
Robinson Healthcare’s UK manufacturing sites are located near Worksop, Nottinghamshire and in Taunton, Somerset. Robinson also operates a manufacturing facility in Hefei, Anhui Province, China. Robinson Healthcare has clean-room packing and production capability, highly automated wipes production and fluid mixing facilities, injection moulding and metal working capabilities and extensive, cotton-based medical absorbent production facilities.
Originally based in Chesterfield, Robinson Healthcare was founded in 1839 and moved into the production of surgical dressings in the 1850s as a result of the demands created by The Crimean War.
The Animalintex brand of veterinary medicinal products was launched in the 1930s. It continues to be the global market-leading veterinary medicinal poultice for equine application. Today Robinson Healthcare employs 208 people.
James Steele, Chief Executive of Vernacare, comments: “Robinson Healthcare and Vernacare are complementary businesses with their respective focus on the manufacture of single-use disposable medical products within infection prevention and surgical space. Vernacare’s international reach will help to build Robinson Healthcare further and continue to realise the vision set by the team at Robinson Healthcare’.
KPMG Corporate Finance acted as sellside advisors to the shareholders of Robinson Healthcare, as well as providing financial due diligence and tax services. The Company’s legal advisors were Wake Smith.
The Vernacare team’s legal advisors were Eversheds Sutherland, and buyside financial due diligence was provided by PWC.
Vernacare is backed by H.I.G. Capital, a leading global alternative investment firm with $43 billion of equity capital under management.